Arcus Biosciences Inc.

• A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (ARC-20) Recruiting
  2024-519142-70-00 Phase I (Other) 1 country
• Randomized Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Ade… Recruiting
  2024-513317-12-00 Phase III 9 countries QUEMLICLUSTAT
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc… Recruiting
  2024-515023-11-00 Phase III 8 countries AB521
• A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin… Ended
  2023-507522-16-00 Phase III 9 countries DOMVANALIMAB; ZIMBERELIMAB
• A safety and efficacy study of treatment combinations with and without chemotherapy in adult patients with advanced upper gastrointestinal t… Ended
  2024-511917-40-00 Phase II 1 country DOMVANALIMAB; QUEMLICLUSTAT; ZIMBERELIMAB
• Phase 3 Study Comparing Zimberelimab with Domvanalimab to Pembrolizumab in Advanced Non-Small Cell Lung Cancer Ended
  2022-503071-28-00 Phase III 4 countries DOMVANALIMAB; PEMBROLIZUMAB; ZIMBERELIMAB
• A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12) Ended
  2024-511116-25-00 Phase I 2 countries
• A Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer Ended
  2024-511158-36-00 Phase I/II 3 countries ETRUMADENANT; QUEMLICLUSTAT; ZIMBERELIMAB

Showing 1–8 of 8 trials